-- WU-CART-007 granted FDA Orphan Drug Designation for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) ---- WU-CART-007 is the…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, March 9, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read MoreWU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA WU-CART-007 demonstrates robust safety profile and exhibits strong CD7-specific anti-tumor activity in…
Read MoreWugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function Lead product candidate…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, November 9, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, November 4, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read MoreProceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by…
Read MoreBiotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the companyST. LOUIS, MO, and SAN…
Read MoreST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…
Read MoreCopyright © 2024 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design
